795.35
0.91%
7.16
After Hours:
795.30
-0.05
-0.01%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co Stock (LLY) Latest News
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? - The Motley Fool
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Eli Lilly Stock Pops After Biden Proposes Medicare Cover Obesity Drugs. Is LLY Stock A Buy? - Investor's Business Daily
Eli Lilly shares jump on two big updates and Jim Cramer is so here for it - CNBC
Eli Lilly, Amazon lead market cap stock movers on Tuesday - Investing.com
Eli Lilly Stock Is Rising Tuesday: What's Going On? - Benzinga
Eli Lilly & Co. (LLY) and Novo Nordisk (NVO) gain on Biden's GLP-1 proposal - StreetInsider.com
Jim Cramer on Eli Lilly and Company (LLY): ‘It’s Valuable’ - Insider Monkey
Eli Lilly Stock Price | LLY Stock Quote, News, and History - Markets Insider
Goldman Sachs: Eli Lilly and Company (LLY) Is A Top Growth Investor Stock - Yahoo Finance
Healthcare Stocks Got Crushed After the Election—Is It Time to Buy? - Morningstar
ELI LILLY AND COMPANY (LLY) - MSN
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs - Benzinga
Kisunla From Eli Lilly - Pharmacy Times
Is Now a Good Time to Buy the Dip in Eli Lilly Stock? - The Motley Fool
Eli Lilly, Verge announce milestones in ALS collaboration - Yahoo Finance
Eli Lilly Teams With Laekna For Innovative Obesity Treatment - Finimize
Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’ - Insider Monkey
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug - Reuters
Oceanside Unified takes on Eli Lilly and CVS Caremark in insulin pricing lawsuit - CBS News 8
Eli Lilly and China-based biotech Laekna team on obesity drug - TipRanks
Eli Lilly in pact with Chinese biotech for novel weight loss therapy - Seeking Alpha
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Australia
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday - Investing.com
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity - BioSpace
Lilly to develop ALS therapeutics against targets identified under Verge collaboration - BioWorld Online
Is It Time to Sell Eli Lilly and Pfizer Stocks? - The Motley Fool
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley - Yahoo Finance
Eli Lilly: Procter & Gamble CEO joins board - Marketscreener.com
Eli Lilly and Company (LLY) Announces Board Changes: Jon Moeller Joins, Karen Walker Resigns - GuruFocus.com
Eli Lilly & Co Appoints Procter & Gamble CEO to Board - TipRanks
Eli Lilly appoints Jon Moeller to board of directors - TipRanks
Lilly announces changes on board of directors - Investors | Eli Lilly and Company
Eli Lilly & Co. stock rises Tuesday, still underperforms market - MarketWatch
Eli Lilly & Co. (LLY) Announces Board Changes - StreetInsider.com
Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley - Yahoo Finance
Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial - CNBC
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip? - Benzinga
Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss - TipRanks
Here’s Why Eli Lilly and Company (LLY) is on Detractors’ List of Madison Sustainable Equity Fund - Yahoo Finance
Lilly’s Lp(a) targeting candidate muvalaplin meets primary endpoint in Phase 2 trial - World Pharmaceutical Frontiers
Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease - OutSourcing-Pharma.com
Lilly pill cuts genetic form of cholesterol nearly 86% in study - Reuters.com
Cramer's Lightning Round: Eli Lilly is a buy - NECN
Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels - Seeking Alpha
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs - Reuters
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):